RT Journal Article SR Electronic T1 Third-Line Trabectedin for a Metastatic Desmoplastic Small Round Cell Tumour Treated with Multimodal Therapy JF Anticancer Research JO Anticancer Res FD International Institute of Anticancer Research SP 3683 OP 3688 VO 34 IS 7 A1 ANNA ELISABETTA BRUNETTI A1 SABINA DELCURATOLO A1 VITO LORUSSO A1 LOREDANA PALERMO A1 ANGELO DI GIORGIO A1 SALVATORE PISCONTI A1 NICOLA SILVESTRIS YR 2014 UL http://ar.iiarjournals.org/content/34/7/3683.abstract AB Background: Desmoplastic small round cell tumour (DSRCT) is a rare and aggressive cancer that usually develops in the peritoneal cavity of young males. Its prognosis is dismal, with current treatment options including the combination of multi-agent chemotherapy, aggressive surgery, radiation therapy, and autologous stem cell transplantation. Hyperthermic intraperitoneal chemotherapy (HIPEC) may also be an option. Case Report: Herein we report the administration of the marine-derived multi-target antineoplastic agent, trabectedin, in a patient with DSRCT, heavily pre-treated with conventional multi-agent chemotherapy, HIPEC, and surgery. Results: The patient achieved a prolonged partial response and an extended period of stable disease with third-line trabectedin, following disease progression after conventional multi-agent chemotherapy, HIPEC, and surgery. Conclusion: Trabectedin may be a treatment option in multimodal therapy for the management of DSRCT and warrants further research to explore the impact of trabectedin in the treatment of this disease.